Shares

3 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q4 2019

Jan 08, 2020

SELL
$10.43 - $17.67 $1,992 - $3,374
-191 Closed
0 $0
Q1 2018

Apr 19, 2018

BUY
$19.43 - $34.95 $699 - $1,258
36 Added 23.23%
191 $4,000
Q3 2017

Oct 30, 2017

BUY
$15.16 - $25.75 $2,349 - $3,991
155
155 $4,000

Others Institutions Holding NTLA

About Intellia Therapeutics, Inc.


  • Ticker NTLA
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 76,011,800
  • Market Cap $775M
  • Description
  • Intellia Therapeutics, Inc., a genome editing company, focuses on the development of therapeutics. The company's in vivo programs include NTLA-2001, which is in Phase 1 clinical trial for the treatment of transthyretin amyloidosis; and NTLA-2002 for the treatment of hereditary angioedema, as well as other liver-focused programs comprising hemoph...
More about NTLA
Track This Portfolio

Track Cribstone Capital Management, LLC Portfolio

Follow Cribstone Capital Management, LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Cribstone Capital Management, LLC, based on Form 13F filings with the SEC.

News

Stay updated on Cribstone Capital Management, LLC with notifications on news.